Jørgen Gustav Bramness
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jørgen Gustav Bramness has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Anne Høye
UiT The Arctic University of Norway
7 shared publications Lars Lien
Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Innlandet Hospital Trust, Brumunddal, Norway
6 shared publications- Eline Borger Rognli
Section for Clinical Addiction Research, Oslo University Hospital, Oslo, Norway
5 shared publications - Fredrik A. Walby
National Centre for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5 shared publications Ingeborg Bolstad
Norwegian Institute of Public Health , Post Box 222 Skøyen, 0213 Oslo
5 shared publicationsJørg Mørland
Norwegian Institute of Public Health, Oslo, Norway; Norwegian Center for Addiction Research (SERAF), Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by SAGE Publications in Nordic Studies on Alcohol and Drugs
Must We Use ASI in the Nordic Region?
- 30 October 2026
- Published by SAGE Publications in Nordic Studies on Alcohol and Drugs
Open AccessMust We Use ASI in the Nordic Region?
- 15 October 2026
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 40 (4)
Worries concerning a scientific review article on the cognitive effects of cannabis in psychotic patients
- 15 October 2026
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 40 (4)
Worries concerning a scientific review article on the cognitive effects of cannabis in psychotic patients
- 24 September 2026
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (S 01) , S13
The development of cannabis and cocaine use in Europe, implications for mental health
- 24 September 2026
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (S 01) , S13
The development of cannabis and cocaine use in Europe, implications for mental health
- Open Access
- 17 June 2026
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (7) , 1581-1587
Alcohol use disorders and related morbidity and mortality after sleeve gastrectomy and Roux-en-Y gastric bypass: a nation-wide registry study (the BAR-REGISTER)
Background: Bariatric surgery provides notable weight loss and metabolic benefits but may also increase the risk of alcohol use disorder (AUD). We investigated whether Roux-en-Y gastric bypass (RYGB) confers higher rates of AUD and related disorders than sleeve gastrectomy (SG) and examined associated morbidity and mortality. Methods: We conducted a retrospective, population-based cohort study using data from the Norwegian Patient Registry and the Norwegian Prescription Database. A total of 17,800 patients underwent RYGB ( n = 12,244) or SG ( n = 5556) between 2008 and 2018. Patients with prior diagnoses related to alcohol or use of medications for AUD were excluded. Incidence rates (IR) for alcohol-related diagnoses were calculated per 1000 person-years; hazard ratios (HR) were derived comparing RYGB to SG. Morbidity was measured as number of specialized healthcare contacts, but also as number of prescriptions/defined daily doses in an exploratory model. Results: Mean postoperative follow-up was 5.7 years (RYGB) and 3.8 years (SG). By 31 December 2018, 576 patients (3.2%) had developed a new alcohol-related diagnosis – an incidence rate of 6.34 per 1000 person-years. The adjusted HR for such diagnoses was 1.69 (95% CI 1.33–2.13, p < 0.001) for patients undergoing RYGB compared to SG. Because mortality did not differ significantly between RYGB and SG, mortality was assessed for the cohort as a whole: patients with alcohol-related diagnoses had an adjusted HR for death of 2.08 (95% CI 1.40–3.08) relative to those without. They also recorded, on average, 5.5 additional contacts in specialist care. Conclusions: Compared with SG, RYGB was associated with a 69% higher risk of alcohol-related diagnoses. Further, given the elevated morbidity and mortality linked to these disorders, enhanced preoperative screening and long-term postoperative monitoring are warranted in modern bariatric practice.
- 17 June 2026
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (7) , 1581-1587
Open AccessAlcohol use disorders and related morbidity and mortality after sleeve gastrectomy and Roux-en-Y gastric bypass: a nation-wide registry study (the BAR-REGISTER)
Background: Bariatric surgery provides notable weight loss and metabolic benefits but may also increase the risk of alcohol use disorder (AUD). We investigated whether Roux-en-Y gastric bypass (RYGB) confers higher rates of AUD and related disorders than sleeve gastrectomy (SG) and examined associated morbidity and mortality. Methods: We conducted a retrospective, population-based cohort study using data from the Norwegian Patient Registry and the Norwegian Prescription Database. A total of 17,800 patients underwent RYGB ( n = 12,244) or SG ( n = 5556) between 2008 and 2018. Patients with prior diagnoses related to alcohol or use of medications for AUD were excluded. Incidence rates (IR) for alcohol-related diagnoses were calculated per 1000 person-years; hazard ratios (HR) were derived comparing RYGB to SG. Morbidity was measured as number of specialized healthcare contacts, but also as number of prescriptions/defined daily doses in an exploratory model. Results: Mean postoperative follow-up was 5.7 years (RYGB) and 3.8 years (SG). By 31 December 2018, 576 patients (3.2%) had developed a new alcohol-related diagnosis – an incidence rate of 6.34 per 1000 person-years. The adjusted HR for such diagnoses was 1.69 (95% CI 1.33–2.13, p < 0.001) for patients undergoing RYGB compared to SG. Because mortality did not differ significantly between RYGB and SG, mortality was assessed for the cohort as a whole: patients with alcohol-related diagnoses had an adjusted HR for death of 2.08 (95% CI 1.40–3.08) relative to those without. They also recorded, on average, 5.5 additional contacts in specialist care. Conclusions: Compared with SG, RYGB was associated with a 69% higher risk of alcohol-related diagnoses. Further, given the elevated morbidity and mortality linked to these disorders, enhanced preoperative screening and long-term postoperative monitoring are warranted in modern bariatric practice.
- Open Access
- 10 June 2026
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 36 (4)
Alcohol harms: the need for prevention and treatment
- 10 June 2026
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 36 (4)
Open AccessAlcohol harms: the need for prevention and treatment
- Open Access
- 1 June 2026
- Published by S. Karger AG in European Addiction Research
- Vol. 32 (2) , 69-71
FDA Approves Reduced Drinking Endpoints for Alcohol Trials: A New Road for Alcohol Treatment?
- 1 June 2026
- Published by S. Karger AG in European Addiction Research
- Vol. 32 (2) , 69-71
Open AccessFDA Approves Reduced Drinking Endpoints for Alcohol Trials: A New Road for Alcohol Treatment?
- Open Access
- 1 June 2026
- Published by Springer Nature in Social Psychiatry and Psychiatric Epidemiology
Patterns of substance-induced psychosis during the COVID-19 pandemic: a national registry study of specialist healthcare contacts
The COVID-19 pandemic affected both substance use patterns and impacted healthcare systems. Substance-induced psychosis (SIP) is a severe mental disorder characterized by severe psychosis triggered by substance use. The number of treated SIP episodes may be sensitive to both changes in substance availability and treatment access. We study investigated whether the monthly prevalence of SIP episodes and mortality among SIP patients changed during the pandemic in Norway, comparing observed cases during 2020-2021 to predictions based on pre-pandemic trends. We analyzed data from the Norwegian Patient Registry (2012-2021), we identified 7,150 individuals diagnosed with SIP (ICD-10 F1x.5). Monthly prevalence rates for overall SIP episodes and substance-specific SIP diagnoses (i.e., due to alcohol, cannabis, amphetamines, or multiple substances) and yearly mortality rates were predicted using ensemble time-series models. Deviations during the pandemic were assessed against 95% prediction intervals derived from pre-pandemic data. The observed monthly prevalence of episodes of any SIP during 2020-2021 largely matched predictions, with some deviations. Alcohol-induced psychosis showed lower than expected rates in 2020 but higher in 2021. Cannabis-induced psychosis rates were below expectations. Amphetamine-induced psychosis and psychosis due to multiple substances showed higher-than-expected rates during lockdowns, with lower rates between lockdowns. Mortality rates among SIP patients for all-cause mortality, suicide, and accidental poisoning during the pandemic were similar to those in the pre-pandemic period. The pandemic did not seem to alter the overall number of SIP episodes. There were, however, some drug-specific changes. This may reflect drug availability, changes in substance use, or changes in healthcare access. A high mortality burden was observed among patients with SIP. However, mortality rates due to all causes, suicide, and accidental poisoning in this group were similar in the pandemic and pre-pandemic periods.
- 1 June 2026
- Published by Springer Nature in Social Psychiatry and Psychiatric Epidemiology
Open AccessPatterns of substance-induced psychosis during the COVID-19 pandemic: a national registry study of specialist healthcare contacts
The COVID-19 pandemic affected both substance use patterns and impacted healthcare systems. Substance-induced psychosis (SIP) is a severe mental disorder characterized by severe psychosis triggered by substance use. The number of treated SIP episodes may be sensitive to both changes in substance availability and treatment access. We study investigated whether the monthly prevalence of SIP episodes and mortality among SIP patients changed during the pandemic in Norway, comparing observed cases during 2020-2021 to predictions based on pre-pandemic trends. We analyzed data from the Norwegian Patient Registry (2012-2021), we identified 7,150 individuals diagnosed with SIP (ICD-10 F1x.5). Monthly prevalence rates for overall SIP episodes and substance-specific SIP diagnoses (i.e., due to alcohol, cannabis, amphetamines, or multiple substances) and yearly mortality rates were predicted using ensemble time-series models. Deviations during the pandemic were assessed against 95% prediction intervals derived from pre-pandemic data. The observed monthly prevalence of episodes of any SIP during 2020-2021 largely matched predictions, with some deviations. Alcohol-induced psychosis showed lower than expected rates in 2020 but higher in 2021. Cannabis-induced psychosis rates were below expectations. Amphetamine-induced psychosis and psychosis due to multiple substances showed higher-than-expected rates during lockdowns, with lower rates between lockdowns. Mortality rates among SIP patients for all-cause mortality, suicide, and accidental poisoning during the pandemic were similar to those in the pre-pandemic period. The pandemic did not seem to alter the overall number of SIP episodes. There were, however, some drug-specific changes. This may reflect drug availability, changes in substance use, or changes in healthcare access. A high mortality burden was observed among patients with SIP. However, mortality rates due to all causes, suicide, and accidental poisoning in this group were similar in the pandemic and pre-pandemic periods.
- Open Access
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
The impact of drinking patterns on the relationship between alcohol use and levels of serum High-Density Lipoprotein Cholesterol (HDL-C)
0. AbstractAlcohol intake is known to influence serum high-density lipoprotein cholesterol (HDL-C), yet how drinking patterns shape this association is less researched. We examined whether frequency of drinking versus amount per occasion were differently related to HDL-C in a large population sample of men. Data were taken from a cross-sectional study of 9,218 men aged 40–79 years in the Tromsø study. Alcohol use was assessed by self-report. Fasting HDL-C was measured using standardized laboratory protocols. Mean alcohol intake was 7.7 g/day and mean HDL-C 1.39 mmol/L. Total alcohol consumption correlated positively with HDL-C (r = 0.155; p < 0.001). In regression models, each additional gram/day was associated with an increase of 0.007 mmol/L HDL-C (95% CI 0.006–0.008; p < 0.001). Drinking frequency showed a positive correlation to HDL-C (r = 0.226; p < 0.001), whereas amount per occasion was inversely related to HDL-C (r = −0.055; p < 0.001). A significant frequency × amount interaction indicated that higher amounts per occasion were linked to lower HDL-C primarily among infrequent drinkers (p < 0.001). The results indicate that the alcohol–HDL-C association was driven by how often alcohol was consumed rather than how much was consumed per occasion. Frequent, lower-dose drinking related to higher HDL-C, whereas infrequent, higher-dose drinking related to lower HDL-C. These findings underscore the need to consider drinking patterns, beyond average intake, when interpreting HDL-C and appraising alcohol-related cardiovascular risk.
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe impact of drinking patterns on the relationship between alcohol use and levels of serum High-Density Lipoprotein Cholesterol (HDL-C)
0. AbstractAlcohol intake is known to influence serum high-density lipoprotein cholesterol (HDL-C), yet how drinking patterns shape this association is less researched. We examined whether frequency of drinking versus amount per occasion were differently related to HDL-C in a large population sample of men. Data were taken from a cross-sectional study of 9,218 men aged 40–79 years in the Tromsø study. Alcohol use was assessed by self-report. Fasting HDL-C was measured using standardized laboratory protocols. Mean alcohol intake was 7.7 g/day and mean HDL-C 1.39 mmol/L. Total alcohol consumption correlated positively with HDL-C (r = 0.155; p < 0.001). In regression models, each additional gram/day was associated with an increase of 0.007 mmol/L HDL-C (95% CI 0.006–0.008; p < 0.001). Drinking frequency showed a positive correlation to HDL-C (r = 0.226; p < 0.001), whereas amount per occasion was inversely related to HDL-C (r = −0.055; p < 0.001). A significant frequency × amount interaction indicated that higher amounts per occasion were linked to lower HDL-C primarily among infrequent drinkers (p < 0.001). The results indicate that the alcohol–HDL-C association was driven by how often alcohol was consumed rather than how much was consumed per occasion. Frequent, lower-dose drinking related to higher HDL-C, whereas infrequent, higher-dose drinking related to lower HDL-C. These findings underscore the need to consider drinking patterns, beyond average intake, when interpreting HDL-C and appraising alcohol-related cardiovascular risk.
- Open Access
- 15 January 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1) , 204
Correction: The epidemiology of major depression among adults in Norway: an observational study on the concurrence between population surveys and registry data – a NCDNOR project
- 15 January 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1) , 204
Open AccessCorrection: The epidemiology of major depression among adults in Norway: an observational study on the concurrence between population surveys and registry data – a NCDNOR project